# Lin Shen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lin-shen-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,077 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 57 |
| i10-index | 205 |
| Last Known Institution | Beijing Tongren Hospital |
| OpenAlex ID | https://openalex.org/A5100720707 |
| ORCID iD | https://orcid.org/0000-0003-1134-2922 |
| Works | 524 |

## Researcher papers

- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial](https://scholariq.org/papers/toripalimab-plus-chemotherapy-in-treatment-naive-advanced-esophageal-squamous/)
- [Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial](https://scholariq.org/papers/sintilimab-versus-placebo-in-combination-with-chemotherapy-as-first-line/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)
- [Epigenetic therapy inhibits metastases by disrupting premetastatic niches](https://scholariq.org/papers/epigenetic-therapy-inhibits-metastases-by-disrupting-premetastatic-niches/)
- [Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line/)
- [Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial](https://scholariq.org/papers/safety-and-antitumour-activity-of-cadonilimab-an-anti-pd-1-ctla-4-bispecific/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Beijing Tongren Hospital](https://scholariq.org/institutions/beijing-tongren-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.